ABSTRACT OF POSTER PRESENTATION (APRIL 17, SATURDAY)

More documents

Recommendations

Info

P2-003 Allergy/Immunology/Rheumatology P2-004 Allergy/Immunology/RheumatologyHIGH MOBILITY GROUP BOX 1 (HMGB1)AND MACROPHAGE MIGRATIONINHIBITORY FACTOR (MIF) IN KAWASAKIDISEASETHE EFFECT OF FK506 ONSUPERANTIGEN-INDUCED STEROIDRESISTANCE OF CUTANEOUSLYMPHOCYTE-ASSOCIATED ANTIGEN CD4 TCELLSTakayuki Hoshina 1 , Koichi Kusuhara 2 , KazuyukiIkeda 3 , Mitsumasa Saito 4 , Toshiro Hara 5Pediatrics, Graduate School of Medical Sciences, Kyushu University 1 ,Department of Pediatrics, University of Occupational and EnvironmentalMedicine 2 , Department of Pediatrics, Graduate School of MedicalSciences 3 , Pediatrics, Kyushu university 4 , Department of Pediatrics,Graduate School of Medical Sciences, Kyushu University, Japan 5Liang-Shiou Ou, Jing-Long HuangDivision of Allergy, Asthma and Rheumatology, Department of Pediatrics, ChangGung Memorial Hospital, and Chang Gung University, Taoyuan, Taiwan.OBJECTIVE: To investigate whether twoproinflammatory cytokines, high mobility group box1 (HMGB1) and macrophage migration inhibitoryfactor (MIF) are involved in the development ofKawasaki Disease (KD).METHODS: Twenty-seven patients with KD wereincluded in this study. Eleven patients with sepsisand 28 healthy children served as controls. Serumlevels of HMGB1 and MIF were measured bycorresponding enzyme-linked immunosorbent assaykits, respectively. Real-time polymerase chainreaction was used to quantify the expression levels ofgenes encoding receptor for advanced glycation endproducts (RAGE), an HMGB1 receptor and CD74,an MIF receptor in peripheral blood mononuclearcells.RESULTS: Serum levels of HMGB1 and MIF inKD patients were the highest in the early acute phaseand gradually decreased after defervescence. SerumHMGB1 and MIF levels in KD patients weresignificantly higher than those in controls (HMGB1,P< 0.001; MIF, P< 0.01). The expression levels ofthe RAGE gene and CD74 gene in KD patients weresignificantly higher than those in controls (RAGE,P< 0.001; CD74, P< 0.01).CONCLUSIONS: These data suggest that HMGB1and MIF play an important role in immune responsesin KD patients.[Keywords]Kawasaki disease, High mobility group box-1,Macrophage migration inhibitory factor, Receptor for advancedglycation end products, CD74OBJECTIVE: Atopic dermatitis is a chronicinflammatory skin disease involving colonization bysuperantigen secreting Staphylococcus aureus.Superantigens are thought to play an important role ininducing inflammatory responses. This study is todetermine the effect of FK506 on superantigen-inducedsteroid resistance of cutaneous lymphocyte-associatedantigen CD4 T cells.METHODS: CD4 + CLA + T cells were isolated bymagnetic microbeads and cell proliferation wasmeasured by [ 3 H]-thymidine incorporation with differentstimulators and suppressors. Flow cytometry for surfacemarkers were determined.MAIN RESULTS: The proliferation of purifiedCD4 + CLA + or CD4 + CLA - T cells with anti-CD3stimulation with presence the APCs were sensitive to theinhibition of dexamethasone (DEX). The inhibition ratesof 10 -6 M DEX were 78.4±20.1% for CD4 + CLA + cellsand 70.1 ± 19.4% CD4 + CLA - T cells. The proliferationof purified CD4 + CLA + or CD4 + CLA - T cells withstaphylococcal enterotoxin B (SEB), stimulation withpresence the APCs were insensitive to the inhibition ofDEX, and the inhibition rate of 10 -6 M DEX were39.6±33.0% and 37.6±43.3% for CD4 + CLA + andCD4 + CLA - T cells. Tacrolimus (FK506), however, washighly effective at inhibiting SEB-induced T cellactivation. SEB-induced CD4 + CLA + and CD4 + CLA - Tcells proliferation both were significantly suppressed byFK506 in the presence APCs. The inhibition rates of 10 -6M FK506 were 90.8 ± 20.0% and 88.5 ± 9.8% forCD4 + CLA + and CD4 + CLA - T cells.CONCLUSION: Superantigen can induce steroidresistance on CD4 + CLA + and CD4 + CLA - T cells withpresence of APCs. However, the suppressive function ofFK506 might revere superantigen- induced steroidresistance.256
P2-005 Allergy/Immunology/Rheumatology P2-006 Allergy/Immunology/RheumatologyANALYSIS OF CLINICAL AND MOLECULARCHARACTERISTICS OF WISKOTT-ALDRICHCLINICAL AND IMMUNE EFFECTS OFETANERCEPT USED IN JIASYNDROME IN 24 PATIENTS FROM 23UNRELATED CHINESE FAMILIESXiaodong Zhao, Zhi-yong Zhang, Hui-qin Xiao ,Li-pingJiang , Yu Zhou, Qin Zhao, Jie Yu, Wei Liu, Xi-qiangYangDivision of Nephrology and Immunology, Children's Hospital of ChongqingMedical University, Chongqing ChinaCaifeng LI, Xiao-Hu HE, Xiao-Hua TAN, Feng-Dan YUBei Jing children’s hospital affiliated to Capital Medical University, ChinaThe clinical data of 24 children with Wiskott-Aldrichsyndrome (WAS) from 23 unrelated Chinese familieswere reviewed in the present study. WAS protein(WASP) expression in peripheral blood mononuclearcells (PBMCs) was examined by flow cytometry;WASP gene was amplified by PCR and directlysequenced to analyze mutations of the WASP gene inpatients and their female relatives. Flow cytometryanalysis of 21 cases showed that 18 cases wereWASP-negative and three had partially WASPexpression. WASP gene analysis revealed mutationsin 23 patients, including 5 missense mutations, 4nonsense mutations, 4 deletion mutations, 3 insertionmutations, 6 splice site mutations and one complexmutation, among which, 20 unique mutations weredetected, including 7 novel mutations (168 C>A,747-748 del T, 793-797del C, 1185 ins C, Dup1251-1267,1277 insA and 1266 C> G; 1267-1269delC). Five WAS children underwent stem celltransplantation. After two months of transplantation,WASP expression was restored to normal in all fivecases whereas one patient died ofcytomegalovirus-induced interstitial lung disease.WASP gene analysis can make a definite diagnosis ofWAS and identify mutation carriers, beneficial fortimely treatment and genetic counseling for childrenwith WAS.[Keywords]Wiskott-Aldrich syndrome; WAS protein; WAS proteingene; clinical phenotype; molecular diagnosisOBJECTS: To discover the Clinical and immune effectsof Etanercept used in JIA.METHOD: During the year of 2006.10~2009.9, 103severe patients of JIA were selected for this study.Before the treatment of Etanercept(0.4mg/kg a dose, 2doses of a week by subcutaneous injection), MTX andprednisone had been regularly used. The course ofEtanercept is 3 months at least. Study contents: (1)Clinical effects of Etanercept: we recorded andanalyzed the level of ACR Pedi (30, 50, 70),inflammation index (ESR, CRP, HGB, WBC, SF) ,bonedestruction and drug side effects, separately on thefollowing periods: before the treatment of Etanerceptand 2 weeks, 1 month, 3 months, 6 months, 12 months,24 months after its use.(2) Immune effects of Etanercept:before the use of Etanercept and 3 months after thetreatment, serum level of TNF-α、IL-1β、IFN-γ and IL-6were detected. SPSS11.5 was used for data statisticalanalysis.RESORTS: All of the 103 patients, 56 cases were male,the other 47 cases were female. The age were between3~14 years,average age was 8-year-old. There were 35cases of JAS, 51 cases of PolyJRA and 17 cases ofSoJRA (5 cases of MAS among SoJRA patients). (1)Clinical effects of Etanercept: After the use ofEtanercept, all the patients felt better, and the ACR Pediwere improved significantly. Inflammation index of mostpatients were decreased significantly (P
Page 1: ABSTRACT OF POSTER PRESENTATION(APR
Page 5 and 6: P2-009 Allergy/Immunology/Rheumatol
Page 23 and 24: P2-045 Neuropsychiatry (Neurology)
Page 40 and 41: P2-079 Nephrology P2-080 Nephrology
Page 46 and 47: P2-091 Nephrology P2-092 Gastroente
Page 48 and 49: P2-095 Gastroenterology P2-096 Gast
Page 50 and 51: P2-101 Gastroenterology P2-102 Gast
Page 52 and 53:
P2-105 Gastroenterology P2-106 Gast
Page 54 and 55:
P2-109 Gastroenterology P2-110 Gast
Page 56 and 57:
P2-113 Endocrinology P2-114 Endocri
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
P2-125 Medical Genetics/Metabolism
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
P2-138 General Pediatrics P2-139 Ge
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
P2-158 Neonatology P2-159 Neonatolo
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86:
show all

ABSTRACT OF POSTER PRESENTATION (APRIL 17, SATURDAY)

Create successful ePaper yourself

Delete template?

Save as template?